ASND
Ascendis Pharma A/S · Healthcare · Biotechnology
Nothing qualifies for this view in the current reporting period. Nothing here is placeholder data: when a figure exists in the filings, it appears.
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 4.47M | -1.3% | $889.03M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 2 | Wellington Management ✦ | 1.80M | +95.9% | $357.65M | 0.1% | ▲ Add | 6 | SEC ↗ ×8 |
| 3 | T. Rowe Price ✦ | 1.73M | -8.0% | $343.19M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 4 | Goldman Sachs Group ✦ | 653.01K | n/a | $129.83M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | JPMorgan Chase ✦ | 584.79K | n/a | $116.26M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 6 | BlackRock ✦ (passive) | 451.50K | -4.3% | $89.76M | 0.0% | ▼ Trim | 2 | SEC ↗ ×11 |
| 7 | Morgan Stanley ✦ | 406.76K | n/a | $80.87M | 0.0% | n/c | 1 | SEC ↗ ×9 |
| 8 | Two Sigma Investments ✦ | 183.89K | +5803.2% | $36.56M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 9 | Millennium Management ✦ | 174.60K | +139.6% | $34.71M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 10 | Geode Capital Management ✦ (passive) | 68.05K | +11.9% | $13.53M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 11 | State Street Global Advisors ✦ (passive) | 61.54K | +5.7% | $12.23M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | Arrowstreet Capital ✦ | 60.66K | New | $12.06M | 0.0% | New | 1 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 27.64K | -95.3% | $5.50M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 14 | Marshall Wace ✦ | 17.70K | -84.9% | $3.52M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 15 | D. E. Shaw & Co. ✦ | 3.59K | -50.1% | $712,933 | 0.0% | ▼ Trim | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Arrowstreet Capital | $12.06M | 0.0% |
Exited
| Adage Capital Partners | $79.33M | was 0.1% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 8 holders, 7.94M shares, $34.76M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 1.10K sh @ 245.85 · $270,435
Director · 900 sh @ 246.91 · $222,219
Open-market sales (S)
Officer · 3.00K sh · $810,570
Director · 236 sh · $62,335
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology